Marziyeh Ajdary

Dr. Marziyeh Ajdary

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2018 in Nanomaterials
Verified
Journal Article
Open access
PDF file
MAMarziyeh Ajdary
Marziyeh Ajdary
MMMohammad Amin Moosavi
Mohammad Amin Moosavi
MRMarveh Rahmati
Marveh Rahmati
MFMojtaba Falahati
Mojtaba Falahati
MMMohammad Mahboubi
Mohammad Mahboubi
Rajender S. VarmaRajender S. Varma
Rajender S. Varma
Nanoparticles (NPs) are currently used in diagnosis and treatment of many human diseases, including autoimmune diseases and cancer. However, cytotoxic effects of NPs on normal cells and living organs is a severe limiting factor that hinders their use in clinic. In addition, diversity of NPs and their physico-chemical properties, including particle size, shape, surface area, dispersity and protein corona effects are considered as key factors that have a crucial impact on their safe or toxicological behaviors. Current studies on toxic effects of NPs are aimed to identify the targets and mechanisms of their side effects, with a focus on elucidating the patterns of NP transport, accumulation, degradation, and elimination, in both in vitro and in vitro models. NPs can enter the body through inhalation, skin and digestive routes. Consequently, there is a need for reliable information about effects of NPs on various organs in order to reveal their efficacy and impact on health. This review covers the existing knowledge base on the subject that hopefully prepares us better to address these challenges.

18 June 2018 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMarziyeh Ajdary
Marziyeh Ajdary
MMMohammad Amin Moosavi
Mohammad Amin Moosavi
MRMarweh Rahmati
Marweh Rahmati
MFMojtaba Falahati
Mojtaba Falahati
MMMohammad Mahboubi
Mohammad Mahboubi
Rajender S. VarmaRajender S. Varma
Rajender S. Varma
Nanoparticles (NPs) are widely used in diverse disciplines, including biology, medicine science. The central question that need to be answered is whether NPs have toxic effects on biological cells and molecules or are they safe. The safety of NPs including targeted drug delivery is critical and so is their toxicity in the environment. In recent years, in vitro and in vivo research on animals has generated abundant information about the toxicity of NPs. However, due to varying laboratory conditions, the comparison of the results from ensuing studies is somewhat unreliable. It should be noted that, depending on the type of production, NPs can enter the body through inhalation, skin and via digestive routes. Due to the diversity of NPs and their properties, there is paucity of accurate information on their toxicological effects; particle size, shape, surface area and the chemical levels are considered as key factors in creating health and toxicological effects. Consequently, there is a need for reliable information about their effects on various organs so as to deal with NPs effectively and their impact on health and the environment. This review covers the existing knowledge base on the subject that hopefully prepares us better to address these challenges.

13 May 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FAFatemeh Sadat Amjadi
Fatemeh Sadat Amjadi
ZZZahra Zandieh
Zahra Zandieh
MMmehdi mehdizadeh
mehdi mehdizadeh
MAMarziyeh Ajdary
Marziyeh Ajdary
AAAzin Aghamajidi
Azin Aghamajidi
RAReza Aflatoonian
Reza Aflatoonian
Objective: Despite the treatment of anovulation, infertility is still one of the main complications in PCOS women during reproductive age, which appears to be mainly due to impaired uterine receptivity. This study investigated the transcriptome profiles of endometrium in PCOS patients and healthy fertile individuals as the control group. Material and methods: Total mRNA was extracted from endometrial tissues of PCOS patients (n = 12) and healthy fertile individuals (n = 10) during the luteal phase. After cDNA synthesis, [...] ABSTRACT Objective: Despite the treatment of anovulation, infertility is still one of the main complications in PCOS women during reproductive age, which appears to be mainly due to impaired uterine receptivity. This study investigated the transcriptome profiles of endometrium in PCOS patients and healthy fertile individuals as the control group. Material and methods: Total mRNA was extracted from endometrial tissues of PCOS patients (n = 12) and healthy fertile individuals (n = 10) during the luteal phase. After cDNA synthesis,

24 April 2024 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
SCShahla Chaichian
Shahla Chaichian
ZFZiba Dehghan Firoozabadi
Ziba Dehghan Firoozabadi
SRSamaneh Rokhgireh
Samaneh Rokhgireh
KTKobra Tahermanesh
Kobra Tahermanesh
AKAbolfazl Mehdizadeh Kashi
Abolfazl Mehdizadeh Kashi
MAMarziyeh Ajdary
Marziyeh Ajdary
Background and objective: Endometriosis (EM) involves the peripheral nervous system and causes chronic pain. Sensory nerves innervating endometriotic lesions contribute to chronic pain and influence the growth phenotype by releasing neurotrophic factors and interacting with nearby immune cells. Calcitonin gene-related peptide (CGRP), a pain-signaling neurotransmitter, has a significant role. This study examines the effect of Dienogest (DNG), a hormone therapy used for managing EM -related pain, on serum CGRP levels in EM patients. Materials and methods: The Visual Analog Scale (VAS) assessed pain in diagnosed EM. individuals. Serum samples were obtained to measure CGRP concentration. Participants received a 2 mg/day oral dose of DNG for six months as prescribed treatment. Additional serum samples were collected after this period to measure CGRP levels. Results: In the EM group, 6.7%, 33.3%, and 20% had ovarian EM, ovarian plus uterosacral, and ovarian plus bladder, respectively. The EM group showed higher CGRP serum levels than the control group (80.53 ± 16.13 vs. 58.55 ± 6.93, P < 0.0001). Still, after drug administration, CGRP serum levels significantly decreased compared to pre-treatment levels (69.66 ± 11.53 vs. 80.53 ± 16.13, P < 0.05). The EM group showed higher pain compared to the control group (7.93 ± 1.58 vs. 0.13 ± 0.35, P < 0.0001), but after drug administration, pain significantly decreased compared to pre-treatment levels (1.00 ± 2.00 vs. 7.93 ± 1.58, P < 0.05). Conclusion: DNG administration reduces pain and serum CGRP levels in EM patients, offering the potential for innovative treatments and tailored options. Understanding neurotransmitter roles and drug effects can aid in discovering more effective modulators for these pathways.

29 October 2024 in Middle East Fertility Society Journal
Verified
Journal Article
Open access
PDF file
HMHamidreza Mosleh
Hamidreza Mosleh
SHSedighe Hosseini
Sedighe Hosseini
NHNazanin Hajizadeh
Nazanin Hajizadeh
LMLeila Majdi
Leila Majdi
MAMarziyeh Ajdary
Marziyeh Ajdary
ZMZahra Shams Mofarahe
Zahra Shams Mofarahe
Background: This article provides an overview of the role of neuropeptides in endometriosis. Main body. While the pathogenesis of endometriosis is not discovered exactly yet, researchers have explored endocrine, paracrine, and immunological influences to better understand the disease. Neuropeptides, which play a significant role in regulating communication among endometrial cells, have been extensively studied and found to have effects on neurons and other somatic cells. The interplay between neuropeptides, pain, and the immune response suggests that neuropeptides may play a significant role in the development and progression of endometriosis. Conclusion: We investigate the role of nerve fibers and neuropeptides, estrogen and estrogen receptors, and new biomarkers in promoting inflammation and pain in endometriosis. Further research should focus on the roles and therapeutic potential of neuropeptides in endometriosis.

26 March 2024 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
SCShahla Chaichian
Shahla Chaichian
FKFatemeh Khodabandehloo
Fatemeh Khodabandehloo
LHLadan Haghighi
Ladan Haghighi
AGAzam Govahi
Azam Govahi
MMMehdi Mehdizadeh
Mehdi Mehdizadeh
Rajender S. VarmaRajender S. Varma
Rajender S. Varma